TRVN (Trevena) Risk Assessment

View and export this data going back to 2014. Start your Free Trial

What is Trevena Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Trevena is: No Data: Cannot be evaluated.

Competitive Comparison of Trevena's Risk Assessment

For the Biotechnology subindustry, Trevena's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Trevena's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Trevena's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Trevena's Risk Assessment falls into.

Save Embed

;

Save Embed

;

Trevena (OTCPK:TRVN) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Trevena Risk Assessment Related Terms

Thank you for viewing the detailed overview of Trevena's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Trevena Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Trevena Inc (OTCPK:TRVN) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

955 Chesterbrook Boulevard, Suite 110, Chesterbrook, PA, USA, 19087

Website

https://www.trevena.com

Trevena Inc is an American biopharmaceutical company focused on developing and commercializing novel medicines for patients affected by central nervous system, or CNS, disorders.

Executives

Mark Corrigan	director
Mark Demitrack	officer: SVP, Chief Medical Officer	955 CHESTERBROOK BOULEVARD, SUITE 200, CHESTERBROOK PA 19087
Robert T Yoder	officer: SVP, Chief Business Officer	955 CHESTERBROOK BOULEVARD, SUITE 110, SUITE 200, CHESTERBROOK PA 19087
Carrie L. Bourdow	director, officer: President & CEO	C/O TREVENA, INC., 1018 WEST 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Patricia M. Drake	officer: SVP, Chief Commercial Officer	245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142
Barry Shin	officer: SVP, CFO	C/O TREVENA, INC., 955 CHESTERBROOK BLVD, SUITE 110, CHESTERBROOK PA 19087
Marvin Johnson	director	C/O TREVENA, INC., 955 CHESTERBROOK BOULEVARD, STE. 110, CHESTERBROOK PA 19087
Barbara Yanni	director	1018 W. 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Moulder Leon O Jr	director	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Jason Raleigh Nunn	director	1119 ST. PAUL STREET, BALTIMORE MD 21202
Scott Braunstein	director	C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Michael R Dougherty	director	C/O ADOLOR CORP, 700 PENNSYLVANIA DR, EXTON PA 19341
Anne M. Phillips	director	C/O TREVENA, INC., 1018 WEST 8TH AVENUE, KING OF PRUSSIA PA 19406
Scott Applebaum	officer: CLCO; SVP, Regulatory Affairs	C/O TREVENA INC., 955 CHESTERBROOK BOULEVARD, SUITE 110, CHESTERBROOK PA 19087
John P. Hamill	officer: Int. Prin. Fin. Off. and PAO	4092 NEW HOPE ROAD, FURLONG PA 18925